This bill substantially reorganizes Massachusetts cannabis regulation by replacing the existing Cannabis Control Commission structure with a new three-member commission housed in chapter 6, with appointments split between the governor and attorney general. It sets qualifications, ethics rules, salary levels, quorum and voting requirements, and creates an executive director with independent authority over enforcement and operations. The bill also moves the commission onto state finance and accounting systems and repeals prior provisions tied to the old commission structure.
The bill makes broad changes to the adult-use and medical cannabis statutes. It updates terminology throughout the General Laws from “medical marijuana treatment center” to “medical marijuana establishment,” revises definitions in chapters 94G and 94I, and expands or clarifies licensing, host community agreement, testing, advertising, delivery, and ownership rules. It increases personal possession and transfer limits from 1 ounce to 2 ounces in key provisions, allows limited delivery statewide with a municipal waiver process, authorizes certain advertising and loyalty programs, and permits employee stock ownership plan transactions. It also limits the number of licenses a single licensee may hold, while giving priority consideration to social equity, minority, women, and veteran business applicants.
The bill also changes medical marijuana access and administration. It replaces the prior medical treatment center framework with “medical marijuana establishment” licensing, expands the definition of card holders, creates temporary registrations, and allows the commission to issue additional license classes and limit the number of medical licenses. It authorizes the commission to revoke or suspend a medical use marijuana license for illegal sales and directs the commission to adopt regulations promoting participation by people from communities disproportionately harmed by marijuana prohibition and enforcement.
In addition to regulatory changes, the bill requires multiple studies and reports. The commission must study mental health outcomes of cannabis use, supply and demand in the legal and illegal cannabis markets, the effect of marijuana excise taxes on industry sustainability and illicit-market demand, and the regulation of hemp-derived cannabinoids. These reports are due in 2026 or 2027 and must include recommendations for legislation where appropriate.
Overall, the bill appears aimed at modernizing and centralizing cannabis oversight while expanding market access and clarifying rules for both adult-use and medical cannabis. The general sentiment reflected in the text is reform-oriented and pro-modernization, with a strong emphasis on social equity, market structure, and public health research. The main points of contention likely concern the restructuring of the commission, the expansion of delivery and advertising, the increase in possession limits, the cap on licenses, and the tax and market-study provisions that could affect business viability and illicit-market competition.
The bill would amend chapters 6, 10, 62, 63, 64N, 94C, 94G, 94I, and 270 of the General Laws, while repealing sections 76 and 77 of chapter 10. It would replace the current Cannabis Control Commission framework with a new commission structure, revise licensing and enforcement authority, redefine key cannabis terms, and update medical marijuana law to use “medical marijuana establishment” terminology throughout. It also changes possession and transfer limits, delivery rules, host community agreement standards, license caps, and tax-related references, and it directs the commission to conduct several policy studies and reports that could lead to future legislation.
The bill’s overall tone is reform-minded and administrative rather than punitive, with a clear effort to modernize cannabis law, improve regulatory clarity, and support social equity participation in the industry. The inclusion of expanded delivery, updated licensing categories, and market studies suggests support for a more flexible and data-driven cannabis framework. At the same time, the bill’s restructuring of the commission and its new limits and compliance rules indicate a desire for tighter governance and stronger oversight.
Likely areas of contention include the replacement of the existing commission with a new three-member body, the concentration of authority in the executive director and chair, and the termination and reappointment of all current commissioners. Industry stakeholders may also disagree over the statewide delivery mandate with municipal waiver options, the expanded advertising and loyalty program permissions, the increased possession limits, and the cap on licenses per licensee. Public health advocates may focus on the mental health study, cannabis-induced psychosis reporting, and the implications of expanded access, while business groups may debate the excise tax study, license limits, and delinquency-credit rules affecting cash flow and market consolidation.